SAGE Therapeutics (SAGE) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
August 2, 2022 6:30 AM EDTRolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022
Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD
Enrolling multiple Phase 2 studies across neuropsychiatry and neurology franchises, additional trials expected to initiate throughout 2022
Cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, expected to support operations into 2025
Conference call today at 8:00 a.m. ET
CAMBRIDGE,... More
